Biotech Analyst Pachaiyappan, along with Dr. Jonathan Meyer, Voluntary Clinical Professor of Psychiatry at the University of California, discuss the competitive landscapes in schizophrenia and MDD and Intra-Cellular (ITCI) and J&J’s relevant treatments on an Analyst/Industry conference call to be held on January 22 at 12 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular downgraded to Neutral from Overweight at Piper Sandler
- Intra-Cellular downgraded to Market Perform from Outperform at Leerink
- BofA moves to No Rating on Intra-Cellular after Johnson & Johnson deal
- Intra-Cellular downgraded to Neutral from Outperform at Baird
- J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz